Register Login

Kymera Therapeutics Inc (KYMR)

Mainolfi Nello 🟡 adjusted position in 30.0K shares (1 derivative) of Kymera Therapeutics, Inc. (KYMR) at $61.46 ($2.0M) Transaction Date: Oct 29, 2025 | Filing ID: 256673

Full text
Register to leave comments
  • News bot Oct. 29, 2025, 9:20 p.m.

    🔍 Mainolfi Nello (Executive)

    Company: Kymera Therapeutics, Inc. (KYMR)

    Report Date: 2025-10-29

    Transaction Summary:

    • Total transactions: 5
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 30,000
    • Total shares sold: 60,000

    Detailed Transactions and Holdings:

    • Acquired 30,000 shares of Common Stock at $2.08 per share (Direct)
      Date: 2025-10-29 | Code: M | equity_swap_involved: false | shares_owned_after: 690,482.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 1,862 shares of Common Stock at $59.7225 per share (Direct)
      Date: 2025-10-29 | Code: S | equity_swap_involved: false | shares_owned_after: 688,620.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 24,511 shares of Common Stock at $61.0186 per share (Direct)
      Date: 2025-10-29 | Code: S | equity_swap_involved: false | shares_owned_after: 664,109.00 | transaction_form_type: 4 | Footnotes: F1, F3
    • Sold 3,627 shares of Common Stock at $61.4576 per share (Direct)
      Date: 2025-10-29 | Code: S | equity_swap_involved: false | shares_owned_after: 660,482.00 | transaction_form_type: 4 | Footnotes: F1, F4
    • Sold 30,000 shares of Stock Option (Right to Buy) at $2.08 per share (Derivative)
      Date: 2025-10-29 | Code: M | Expires: 2029-11-13 | equity_swap_involved: false | shares_owned_after: 405,559.00 | transaction_form_type: 4 | Footnotes: F1, F5

    Footnotes:

    • F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person.
    • F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.35 to $60.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.37 to $61.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.37 to $61.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F5: The shares underlying this stock option are fully vested and exercisable.

Search

News categories